<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F2004696-9375-4C0A-AD85-77C5C8426BD2"><gtr:id>F2004696-9375-4C0A-AD85-77C5C8426BD2</gtr:id><gtr:firstName>Klaus</gtr:firstName><gtr:surname>Okkenhaug</gtr:surname><gtr:orcidId>0000-0002-9432-4051</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BBS%2FE%2FB%2F0000C236"><gtr:id>F30D7DD7-B25E-4003-A513-FCEBBB9DBB7C</gtr:id><gtr:title>Roles of PI3K isoforms in lymphocyte development and function</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>BBS/E/B/0000C236</gtr:grantReference><gtr:abstractText>Cells of the immune system constantly monitor their local environment for evidence of infection. B and T lymphocytes (types of white blood cell) have evolved to distinguish self (any tissue in the organism) from non-self (infectious agents). Foreign substances, which include the chemical make-up of bacteria and viruses, stimulate B and T lymphocytes to divide rapidly and produce antibodies and other substances that help rid the body of the infectious agent. B and T cells can recall a previous encounter with a particular organism and mount a faster and more vigorous response to subsequent encounters. However in some cases B and T lymphocytes mistakenly recognise components of different organs as infectious agents. This mistake can lead to autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, juvenile diabetes, systemic lupus erythematosus and other diseases. Phosphoinositide 3-kinases (known as PI3Ks) are a family of enzymes used by the cell to transmit signals from receptors on the outside of the cell to the machinery inside the cell that dictates how a cell behaves. We have previously identified one member of this family called p110?, which plays an important role in transmitting the signals generated when a B or T cell recognises foreign antigens. As a consequence of this discovery, pharmaceutical companies are developing drugs that can interfere with p110? and hence dampen harmful immune responses. More recently we have investigated how two related enzymes, p110? and p110? c,oooperate with p110? to regulate immune responses. This work has revealed a level of redundancy (thave a similar role) between p110? and p110?, whereas p110? is not redundant with p110?. Instead, recent work suggests that p110? may be redundant with p110?. Thus further work will focus on thidentifying how p110? and p110? regulate PI3K signalling downstream of tyrosine kinase linked receptors and how p110? and p110? contribute to G-protein coupled receptor signalling.</gtr:abstractText><gtr:fund><gtr:end>2012-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2008-09-19</gtr:start><gtr:type>EXPENDITURE_PROJECTED</gtr:type><gtr:valuePounds>1810596</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The PI3Kdelta drug idelalisib has been approved for clinical use. Our results provide a mechanistic understanding for why these drugs work particularly well in mature B cell leukaemias.</gtr:description><gtr:firstYearOfImpact>2014</gtr:firstYearOfImpact><gtr:id>57E55D00-6525-41E2-8B89-70C4174FD27B</gtr:id><gtr:impactTypes><gtr:impactType>Societal,Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>544fb808dbd082.14483197</gtr:outcomeId><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>We defined differential roles for PI3Ka and PI3Kd in B cell development and function.
We defined an important role for PI3Kd in regulating the CD8+ T cell response to Listeria monocytogenes. 
We defined a transcriptional profile of Treg lacking PI3Kd and identified CD38 as a marker of activated Treg reduced when PI3Kd is inhibited.</gtr:description><gtr:exploitationPathways>PI3Kd inhibitors have been approved for treatment of B cell malignancies. There are also dual PI3Ka-PI3Kd inhibitors being developed to treat B cell cancers, based in part on our work.</gtr:exploitationPathways><gtr:id>600BA3AE-AC20-414C-B14C-3549BC69A398</gtr:id><gtr:outcomeId>r-2664920578.3986687770262a</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>784157AD-3420-47FA-B699-51DC87CC5180</gtr:id><gtr:title>PI3K? plays a critical role in neutrophil activation by immune complexes.</gtr:title><gtr:parentPublicationTitle>Science signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf4791aaad3ff17c7499e3c358e997f1"><gtr:id>bf4791aaad3ff17c7499e3c358e997f1</gtr:id><gtr:otherNames>Kulkarni S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1945-0877</gtr:issn><gtr:outcomeId>544f6972dc5885.10372598</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57E95D62-5192-4FBD-B9FE-829548A11F14</gtr:id><gtr:title>Blockade of phosphatidylinositol 3-kinase PI3Kd or PI3K? reduces IL-17 and ameliorates imiquimod-induced psoriasis-like dermatitis.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b89b77ad57488f956231b7bf8b249b87"><gtr:id>b89b77ad57488f956231b7bf8b249b87</gtr:id><gtr:otherNames>Roller A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5675d793da577</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3C3B7A2-F7A3-4557-A30A-5671E189D77B</gtr:id><gtr:title>Rules of engagement: distinct functions for the four class I PI3K catalytic isoforms in immunity.</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b655a19e2deeae86c8bdddb8a40588e"><gtr:id>7b655a19e2deeae86c8bdddb8a40588e</gtr:id><gtr:otherNames>Okkenhaug K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn><gtr:outcomeId>5447882b5bb8e2.14528642</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09241DDF-220B-4CC6-A711-9051866EF69E</gtr:id><gtr:title>Pten loss in CD4 T cells enhances their helper function but does not lead to autoimmunity or lymphoma.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89c6ac9c125805e49560618d1b91057b"><gtr:id>89c6ac9c125805e49560618d1b91057b</gtr:id><gtr:otherNames>Soond DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5447882c7a0726.98403486</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01F69136-FB34-4E88-B5FB-5C4743449759</gtr:id><gtr:title>MAPK, phosphatidylinositol 3-kinase, and mammalian target of rapamycin pathways converge at the level of ribosomal protein S6 phosphorylation to control metabolic signaling in CD8 T cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/181788d1197fdc4cae30985077b49b51"><gtr:id>181788d1197fdc4cae30985077b49b51</gtr:id><gtr:otherNames>Salmond RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5447882e375669.52821148</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E161D47-6916-4886-871A-527A3814AA07</gtr:id><gtr:title>The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development.</gtr:title><gtr:parentPublicationTitle>Science signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abff5f3c583fc3f81163ddc836927686"><gtr:id>abff5f3c583fc3f81163ddc836927686</gtr:id><gtr:otherNames>Ramadani F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1945-0877</gtr:issn><gtr:outcomeId>5447882d629934.13542732</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5E8157E-B4C1-4F6E-90C8-00A98748B635</gtr:id><gtr:title>PI3Ks in lymphocyte signaling and development.</gtr:title><gtr:parentPublicationTitle>Current topics in microbiology and immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b655a19e2deeae86c8bdddb8a40588e"><gtr:id>7b655a19e2deeae86c8bdddb8a40588e</gtr:id><gtr:otherNames>Okkenhaug K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0070-217X</gtr:issn><gtr:outcomeId>5447882d921d01.78636776</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BACFAD5F-BDC9-4306-96BE-7538C26A66AE</gtr:id><gtr:title>The p110delta isoform of phosphatidylinositol 3-kinase controls susceptibility to Leishmania major by regulating expansion and tissue homing of regulatory T cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4837756eedd04b2c5e2628d1a72fe42b"><gtr:id>4837756eedd04b2c5e2628d1a72fe42b</gtr:id><gtr:otherNames>Liu D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5447882eaa2635.80334399</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B723D47-1BA0-4BC8-8809-C078643044F2</gtr:id><gtr:title>p110gamma and p110delta isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45ffa0de99c14c1e4c4510e05e864f81"><gtr:id>45ffa0de99c14c1e4c4510e05e864f81</gtr:id><gtr:otherNames>Saudemont A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5447882f1a2640.82261556</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCD116AB-4072-4C8D-8061-F32F6F71CC13</gtr:id><gtr:title>Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c103121161acaf3eb8ec5ba68859ff7"><gtr:id>8c103121161acaf3eb8ec5ba68859ff7</gtr:id><gtr:otherNames>Macintyre AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>56758ea9ef0c5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38D52093-B229-4003-99C5-7F77903744E4</gtr:id><gtr:title>The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b32cc326726985b75a63bd9789742a60"><gtr:id>b32cc326726985b75a63bd9789742a60</gtr:id><gtr:otherNames>Guillermet-Guibert J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5447882fe77294.55996775</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60930081-1BC2-4D1D-83A2-914C0BB2CED5</gtr:id><gtr:title>Inhibition of Phosphoinositide 3-Kinase p110delta Does Not Affect T Cell Driven Development of Type 1 Diabetes Despite Significant Effects on Cytokine Production.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec504cce1b308362ca2cdf476b247914"><gtr:id>ec504cce1b308362ca2cdf476b247914</gtr:id><gtr:otherNames>Barbera Betancourt A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56c207f1880173.23716082</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40111F39-91F6-4F4B-AB5F-1AC6899FE323</gtr:id><gtr:title>Genetic or pharmaceutical blockade of phosphoinositide 3-kinase p110&amp;Icirc;&amp;acute; prevents chronic rejection of heart allografts.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2811385993b8ba4009ef204b1841d089"><gtr:id>2811385993b8ba4009ef204b1841d089</gtr:id><gtr:otherNames>Ying H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5675d6fa1d4d3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2795DC49-639C-44A1-866E-5D27E4FCB31F</gtr:id><gtr:title>The PI3K p110&amp;Icirc;&amp;acute; regulates expression of CD38 on regulatory T cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18aa4e371fa1e255116f708571ea6d0e"><gtr:id>18aa4e371fa1e255116f708571ea6d0e</gtr:id><gtr:otherNames>Patton DT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>544f85b848f5f3.54262628</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0ABC16B9-B20C-4967-84F7-F4A5944FC75B</gtr:id><gtr:title>Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1fe6f280971b7a1152ee3e5d2522299a"><gtr:id>1fe6f280971b7a1152ee3e5d2522299a</gtr:id><gtr:otherNames>Kohlhaas S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5447882f4a5733.51939750</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEF2A8D4-ACBD-4C8E-A3F5-444E4D1007BC</gtr:id><gtr:title>CCL21 mediates CD4+ T-cell costimulation via a DOCK2/Rac-dependent pathway.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f8c0e1a654be9608d54290d1e83dda8"><gtr:id>2f8c0e1a654be9608d54290d1e83dda8</gtr:id><gtr:otherNames>Gollmer K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5447882eda9b15.19245587</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23AC2205-4A4C-4CFA-9CE6-63A2960D4E10</gtr:id><gtr:title>Proliferative signals mediated by CD28 superagonists require the exchange factor Vav1 but not phosphoinositide 3-kinase in primary peripheral T cells.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25f1222712dc6cc481c3e7dee84374ec"><gtr:id>25f1222712dc6cc481c3e7dee84374ec</gtr:id><gtr:otherNames>Gogishvili T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>5447882fada2a0.53296709</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACC570B9-51C4-4384-9B3E-7D46FD78866E</gtr:id><gtr:title>Ribosomal protein S6 kinase 1 signaling regulates mammalian life span.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c751c3b3d40edbf575fd15ce4015cab6"><gtr:id>c751c3b3d40edbf575fd15ce4015cab6</gtr:id><gtr:otherNames>Selman C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>5447882e6b5f27.19358197</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E212A15-DC32-4C31-89AA-1FD7BAE2FAF0</gtr:id><gtr:title>Cross talk between phosphatidylinositol 3-kinase and cyclic AMP (cAMP)-protein kinase a signaling pathways at the level of a protein kinase B/beta-arrestin/cAMP phosphodiesterase 4 complex.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d0157f49a10867cb144a2c597d758b1"><gtr:id>8d0157f49a10867cb144a2c597d758b1</gtr:id><gtr:otherNames>Bj?rgo E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-7306</gtr:issn><gtr:outcomeId>5447882dc14852.42291183</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CC9888C-1530-4EF3-8713-65D983765B2F</gtr:id><gtr:title>Ig gene-like molecule CD31 plays a nonredundant role in the regulation of T-cell immunity and tolerance.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54e22ea8b9a5712de0fb5c6c45e86833"><gtr:id>54e22ea8b9a5712de0fb5c6c45e86833</gtr:id><gtr:otherNames>Ma L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5447882cee66f6.49177394</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F10E9A09-5142-4E8D-A406-B04716C48CE5</gtr:id><gtr:title>Signaling by the phosphoinositide 3-kinase family in immune cells.</gtr:title><gtr:parentPublicationTitle>Annual review of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b655a19e2deeae86c8bdddb8a40588e"><gtr:id>7b655a19e2deeae86c8bdddb8a40588e</gtr:id><gtr:otherNames>Okkenhaug K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0732-0582</gtr:issn><gtr:outcomeId>5447882b9654f5.95125748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51B7F93E-A181-48BF-B8E9-C4F0EBEC4337</gtr:id><gtr:title>PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89c6ac9c125805e49560618d1b91057b"><gtr:id>89c6ac9c125805e49560618d1b91057b</gtr:id><gtr:otherNames>Soond DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5447882df41aa4.46073516</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BBS/E/B/0000C236</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>